3/17
12:30 pm
anab
AnaptysBio (ANAB) had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio (ANAB) had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a "buy" rating on the stock.
3/12
11:22 am
anab
AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.
Medium
Report
AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.
3/11
12:31 am
anab
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible [Yahoo! Finance]
Medium
Report
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible [Yahoo! Finance]
3/10
11:21 am
anab
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/6
12:06 pm
anab
AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.
Low
Report
AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.
3/6
07:32 am
anab
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress [Yahoo! Finance]
Low
Report
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress [Yahoo! Finance]
3/5
08:04 am
anab
AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.
Medium
Report
AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.
3/4
12:59 pm
anab
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference [Yahoo! Finance]
Low
Report
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference [Yahoo! Finance]
3/4
09:49 am
anab
AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.
Medium
Report
AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.
3/4
08:00 am
anab
AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.
High
Report
AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.
3/3
04:34 pm
anab
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/3
04:15 pm
anab
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
High
Report
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
2/12
01:36 am
anab
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? [Yahoo! Finance]
Low
Report
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? [Yahoo! Finance]
2/5
04:15 pm
anab
Anaptys Announces Participation at Upcoming Investor Conferences
Medium
Report
Anaptys Announces Participation at Upcoming Investor Conferences
1/23
05:05 am
anab
AnaptysBio (NASDAQ:ANAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
07:17 am
anab
AnaptysBio (NASDAQ:ANAB) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
AnaptysBio (NASDAQ:ANAB) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/11
07:40 pm
anab
What Investors Should Know About a $163K AnaptysBio Insider Sale [Yahoo! Finance]
Medium
Report
What Investors Should Know About a $163K AnaptysBio Insider Sale [Yahoo! Finance]
1/11
06:56 pm
anab
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally [Yahoo! Finance]
Medium
Report
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally [Yahoo! Finance]
1/10
02:18 am
anab
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Medium
Report
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
1/9
06:10 am
anab
AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/9
04:18 am
anab
AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute [Yahoo! Finance]
Low
Report
AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute [Yahoo! Finance]
1/8
07:18 pm
anab
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty [Yahoo! Finance]
Low
Report
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty [Yahoo! Finance]
1/8
07:02 pm
anab
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary [Yahoo! Finance]
Low
Report
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary [Yahoo! Finance]
1/8
06:00 pm
anab
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
Low
Report
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
1/7
04:06 am
anab
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at UBS Group AG.
Low
Report
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at UBS Group AG.